The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?

07:00 EST 19th January 2019 | BioPortfolio

Summary of "The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?"

This review aims to highlight recent research on the gut microbiome in IBD and the application of microbiome-modulating therapies for the treatment of IBD including the use of the microbiome as an indicator for disease severity and treatment response.


Journal Details

This article was published in the following journal.

Name: Current treatment options in gastroenterology
ISSN: 1092-8472


DeepDyve research library

PubMed Articles [22067 Associated PubMed Articles listed on BioPortfolio]

Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents.

Animal studies showed that germ-free mice inoculated with normal mouse gut bacteria developed obesity, insulin resistance and higher triglyceride levels, despite similar food intake. In humans, an ass...

The microbiome, a new target for ecobiology in dermatology.

The skin is the human body's largest organ colonised by a large community of microorganisms. The ecological community of microorganisms that are present on our body and of the body itself defines the ...

Gut microbiome and cancer immunotherapy.

Microbiome is becoming crucial in that the balance between human health and disease can be mediated by the gut microbiome. The gut microbiome can modulate the host immune system both locally and syste...

Precision Engineers: Bacteriophages Modulate the Gut Microbiome and Metabolome.

The precise and rational manipulation of the gut microbiome may enable new therapies for gut health and disease. In this issue of Cell Host & Microbe, Hsu et al. (2019) reveal that bacteriophage pre...

Decreased Fecal Bacterial Diversity and Altered Microbiome in Children Colonized With Clostridium difficile.

The gut microbiome is believed to play a role in the susceptibility to and treatment of Clostridium difficile infections (CDIs). It is, however, unknown whether the gut microbiome is also affected by ...

Clinical Trials [3551 Associated Clinical Trials listed on BioPortfolio]

Effects of H.Pylori Eradication on Microbiome

The aim of this Project is, within the scope of industrial research, to evaluate the long term effects of H.pylori eradication on microbiome (gut microbiome, upper respiratory tract microb...

Maternal and Neonatal Microbiome

The aim of the study is to characterize and monitor the microbiome of premature infants born in the investigators facility until discharge from the NICU. The investigators will also examin...

Microbiome and Sarcopenia in Patients With Liver Cirrhosis

Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70%...

Food and Microbiome Longitudinal Investigation (FAMiLI)

The NYU Human Microbiome Study Cohort is designed to improve understanding of the role of human microbiome in health and disease. This study will serve as a critical NYU biorepository reso...

Neonatal Microbiome Validity Study

This is a validation study to compare proposed field collection methods with a gold standard collection technique for microbiome analysis of stool and breast milk samples.

Medical and Biotech [MESH] Definitions

The use of pre-treatment imaging modalities to position the patient, delineate the target, and align the beam of radiation to achieve optimal accuracy and reduce radiation damage to surrounding non-target tissues.

All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT.

A technique for the treatment of neoplasms in which an isotope is introduced into target cells followed by irradiation with thermal neutrons.

A technique for the treatment of neoplasms, especially gliomas and melanomas in which boron-10, an isotope, is introduced into the target cells followed by irradiation with thermal neutrons.

The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.

Quick Search


DeepDyve research library

Searches Linking to this Article